Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
TFPI encodes a protease inhibitor that regulates the tissue factor (TF)-dependent pathway of blood coagulation.
Showing 10 out of 34 products:
Human TFPI Protein expressed in Escherichia coli (E. coli) - ABIN1080946
Gamperl, Plattfaut, Freund, Quecke, Theophil, Gieseler: Extracellular vesicles from malignant effusions induce tumor cell migration: inhibitory effect of LMWH tinzaparin. dans Cell biology international 2016
Human TFPI Protein expressed in Escherichia coli (E. coli) - ABIN2123670
Ranasinghe, Duke, Harvie, McManus: Kunitz-type protease inhibitor as a vaccine candidate against schistosomiasis mansoni. dans International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2017
Human TFPI Protein expressed in Human Cells - ABIN2003062
Broze, Warren, Novotny, Higuchi, Girard, Miletich: The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. dans Blood 1988
Show all 5 Pubmed References
endogenous TFPI from vascular smooth muscle cells inhibited ferric chloride-induced arterial thrombosis without causing hemostatic effects
TFPI-1 interacts with AMOT (Montrer AMOT Protéines), which led to a decrease in the phosphorylation of YAP (Montrer YAP1 Protéines) and further increased the genes expression of the proliferation and migration involved. Our results further confirmed that atherosclerosis was a localized disease.
Results suggest that endothelial cell-anchored TFPI controls lung tumor metastasis, and does so largely through the inhibition of local TF-induced thrombin (Montrer F2 Protéines) generation and the regulation of the lung microenvironment in mice.
Data argue against an important role for endogenous TFPI in the antibacterial, inflammatory and procoagulant response during pneumococcal pneumonia.
TFPI has an anti-proliferative role in TNF-alpha (Montrer TNF Protéines) stimulated-VSMCs at least partly by interfering with the MCP-3 (Montrer CCL7 Protéines)/CCR2 (Montrer CCR2 Protéines) pathway and then via suppression of the ERK1/2 and PI3K/AKT (Montrer AKT1 Protéines) signaling pathways
Results demonstrate that TFPI physiologically modulates thrombin (Montrer F2 Protéines)-dependent platelet activation in a manner that is required for successful embryonic development
Tissue factor (Montrer F3 Protéines) plays a hitherto unreported role in the generation of macrophage migratory inhibitory factor by vascular smooth muscle cells in atherosclerosis-prone ApoE (Montrer APOE Protéines)(-/-) mice.
The increased plasmin (Montrer PLG Protéines) generation during the early stages of sepsis could cleave/inactivate TFPI and thus lead to thrombotic complications.
structural features within residues of the 39-loop contribute to the resistance of FIXa (Montrer ETFB Protéines) to inhibition by plasma inhibitors ZPI (Montrer SERPINA10 Protéines) and TFPI.
PAK1 (Montrer PAK1 Protéines) negatively regulates the expression of TFPI and additionally contributes to increased TF activity.
Patients with early onset preeclampsia are characterised by an attenuated coagulation response characterised by reduced thrombin (Montrer F2 Protéines) generation stimulated by low-dose TF and elevated plasma TFPI activity.
Developed functional protein S assays that measure both the activated protein C (Montrer PROC Protéines)- and TFPI-cofactor activities of protein S in plasma, which are hardly if at all affected by the FV Leiden mutation.
These data indicate that both isoforms of TFPI are present in advanced plaques and that anti-inflammatory M2 macrophages may be a potential source of TFPI.
Among the various candidate genes involved in acute rejection, CD47 (Montrer CD47 Protéines) inhibits monocyte/macrophage-mediated phagocytosis by identifying the CD47 (Montrer CD47 Protéines) signal regulatory protein alpha (SIRP (Montrer SIRPA Protéines)-alpha) as self/non-self. Tissue factor pathway inhibitor (TFPI) is involved in the regulation of the coagulation pathway and is able to bind to another ligand of CD47 (Montrer CD47 Protéines), thrombospondin-1 (TSP-1 (Montrer THBS1 Protéines)).
Tissue Factor Pathway Inhibitor Gene Polymorphism is associated with response to therapy in Colorectal Cancer.
For the first time, we show that a TFPI variant is significantly associated with fibrinogen levels and risk of coronary artery disease.
miR (Montrer MLXIP Protéines)-27a/b and miR (Montrer MLXIP Protéines)-494 regulate TFPIalpha expression; there may be a role of these miRNAs in the estrogen-mediated downregulation of TFPIalpha
Genetic variations of the TFPI genes seem to be related with coronary artery disease, which likely cooperate with metabolic risk factor (diabetes mellitus) and play critical roles in the pathogenesis of coronary artery disease in Han Chinese.
Cleavage of FV at Arg(1545) , which abolishes the anticoagulant properties of FV and commits FV to the procoagulant pathway, is inhibited by binding of the TFPIalpha C-terminus to the FV acidic region
The aim of this study was to evaluate the concentration of TF and its inhibitor TFPI in blood plasma, the impact of traditional and non-traditional cardiovascular risk factors on their concentration and the impact of both markers of haemostasis on the severity of subclinical atherosclerosis.
Upregulated TF expression and increased plasma TF level during reperfusion period, reduced plasma TFPI-1 level during reperfusion period.
This gene encodes a protease inhibitor that regulates the tissue factor (TF)-dependent pathway of blood coagulation. The coagulation process initiates with the formation of a factor VIIa-TF complex, which proteolytically activates additional proteases (factors IX and X) and ultimately leads to the formation of a fibrin clot. The product of this gene inhibits the activated factor X and VIIa-TF proteases in an autoregulatory loop. The encoded protein is glycosylated and predominantly found in the vascular endothelium and plasma in both free forms and complexed with plasma lipoproteins. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been confirmed.
extrinsic pathway inhibitor
, lipoprotein-associated coagulation inhibitor
, uncharacterized protein LOC100155068
, tissue factor pathway inhibitor